Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.,Ltd (SZSE: 301130)
Health Care · Pharmaceuticals · CN
CN¥31.38
+1.72% today · -4.2% 1Y
Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.,Ltd (SZSE: 301130) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $352.41M and employs 313 people.
Over the last twelve months the share price has lost 4.2%, trading between 21.88 and 39.98.
Tweenvest scores Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.,Ltd across four factors: quality 67/100, value 37/100, growth 0/100, dividend 17/100. Its strongest factor is quality.
301130 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $352.41M
- Revenue (TTM)
- $34.58M
- P/E
- 105.31
- EPS
- 0.30
- Dividend yield
- 0.46%
- Beta (5Y)
- 0.47
- 52-week high
- CN¥39.98
- 52-week low
- CN¥21.88
- Avg volume (3M)
- —
- Shares outstanding
- 75.49M
- Employees
- 313
- Next earnings
- —
About Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.,Ltd
Jilin Province Xidian Pharmaceutical Sci-Tech Development Co.,Ltd specializes in the comprehensive process of pharmaceutical goods, encompassing their research, development, production, and distribution. Its portfolio features therapeutic drugs addressing conditions such as anemia, mental health issues, cardiovascular ailments, and various cancers. The firm also supplies traditional Chinese medicines and essential raw materials. These medicinal products are available in oral solid forms and as freeze-dried powder for injections. Established in 1993, the company operates from its headquarters in Panshi, China.
- ISIN
- CNE1000058C4
- Founded
- 1990
- Listed since
- Feb 23, 2022
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,244.96 | -0.83% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $272.49 | +0.83% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $150.73 | -1.19% |
| Roche Holding AGSWX: ROP | $373.91B | CHF370.40 | -1.38% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £121.10 | -1.06% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.03 | -0.14% |
Figures last refreshed Aug 18, 2026.